Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on March 17, 2004, Boehringer Ingelheim Chemicals Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.
| Drug | Schedule |
|---|---|
| Amphetamine (1100) | II |
| Methylphenidate (1724) | II |
| Methadone (9250) | II |
| Methadone Intermediate (9254) | II |
| Dextropropoxyphene, bulk (non-dosage forms) (9273) | II |
| Levo-alphacetylmethadol (9648) | II |
| Fentanyl (9801) | II |
The firm plans to manufacture the listed controlled substances for formulation into finished pharmaceuticals.
Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than July 26, 2004.
Dated: May 5, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 04-11820 Filed 5-25-04; 8:45 am]
BILLING CODE 4410-09-M